Abiologics uses generative AI and high‑throughput chemical protein synthesis to design and produce Synteins™, a new class of programmable, protease‑resistant, immune‑silent biologics.
Funding
Funding not disclosed
Founders
Product
Problem
Current biologic medicines rely on natural protein building blocks that are recognized and degraded by the body, limiting their stability, modifiability, and therapeutic reach across diseases such as cancer, immune disorders, and metabolic conditions.
Solution
Abiologics addresses these limitations with its AI‑driven platform that combines generative computational design and high‑throughput chemical protein synthesis to create Synteins™—synthetic, protease‑resistant, immune‑silent biologics. By designing proteins from non‑natural building blocks, the platform can engineer molecules with programmable functions and enhanced pharmacokinetic properties that are unattainable with conventional biologics. The chemically synthesized Synteins™ retain desired biological activity while avoiding degradation and immune detection, enabling targeted therapeutic action across oncology, immunology, and metabolic disease areas. This approach accelerates the development of next‑generation medicines for patients with unmet medical needs.
Target Audience
Primary customers are pharmaceutical and biotech companies developing treatments for oncology, immunology, and metabolic diseases that require biologics with enhanced stability and reduced immunogenicity.
Features
- Generative AI algorithms that design protein‑inspired molecules using entirely synthetic amino acid building blocks
- High‑throughput chemical protein synthesis enabling rapid production of designed Synteins™ at scale
- Engineered protease resistance to extend circulating half‑life and improve stability
- Immune‑silent architecture that minimizes immunogenicity and adverse immune responses
- Programmable functional domains allowing precise targeting of disease pathways in oncology, immunology, and metabolism
- Modular design framework providing near‑infinite degrees of freedom for tailoring therapeutic properties